Rheumatoid arthritis targets the knee more often and more aggressively than many people expect. While the disease famously begins in the small joints of the hands and feet, the knee is one of the large joints most frequently drawn into the process, and because it bears so much of your body weight, the consequences tend to be felt earlier and more dramatically than in other joints. The mechanism is fundamentally different from the wear-and-tear damage of osteoarthritis: in RA, your immune system drives the destruction from the inside out, eating away at cartilage and bone through a process that can be slowed but, once it gains momentum, is difficult to reverse.
What Happens Inside an RA Knee
The hallmark of rheumatoid arthritis in any joint is persistent inflammation of the synovium, the thin membrane lining the joint capsule. In a healthy knee, the synovium produces a small amount of lubricating fluid. In RA, immune cells invade the synovium and cause it to thicken dramatically, forming a mass of aggressive tissue called pannus. This pannus behaves almost like a slow-growing tumor: it creeps over the surface of the cartilage and begins to erode it, eventually reaching the bone underneath.
Electron microscopy studies have shown at least three distinct patterns of cartilage destruction at the pannus border. In some areas, tiny new blood vessels push into the cartilage surrounded by dense clusters of inflammatory cells, and the cartilage degenerates around these clusters. In others, specialized cells that digest tissue invade directly. In a third pattern, a fibrous layer of pannus simply sits on top of the cartilage while damage accumulates beneath it. The net result is that cartilage is dissolved by infiltrating cells, and the smooth joint surface is gradually replaced by rough, irregular tissue.
This destruction is what separates RA from a simple flare of inflammation. Even when the knee feels relatively calm between episodes, the pannus can continue its work, leading to progressive cartilage loss, narrowing of the joint space, and eventually erosion of the underlying bone and damage to ligaments and other soft tissues.
Recognizing RA Knee Symptoms
The classic presentation is a warm, swollen knee that is stiff for prolonged periods in the morning, usually more than 30 minutes. Unlike osteoarthritis stiffness, which tends to ease quickly with movement, RA stiffness can take hours to loosen up. Both knees are often affected, though not always at the same time or to the same degree. Pain is typically worst with weight-bearing and can worsen at night. Over time, the joint may develop a visible deformity, most commonly a valgus (“knock-knee”) alignment, as the cartilage and ligaments on one side erode faster than the other.
One complication that catches many people off guard is a Baker’s cyst, a fluid-filled swelling at the back of the knee. In a study of 367 RA patients with knee involvement, Baker’s cysts were diagnosed in about 15% of them, and roughly a quarter of those cysts ruptured. When a Baker’s cyst ruptures, fluid leaks into the calf, causing sudden pain and swelling that can mimic a blood clot. The study found that the cysts were tied to local knee inflammation rather than to how active the RA was throughout the body, and patients whose RA affected only the knee were at higher risk. In rare cases, these cysts grow quite large: one published report described a cyst measuring 95 by 26 millimeters extending from the back of the knee nearly to the lower third of the calf.
How the Knee Is Assessed
Standard X-rays remain the baseline tool for tracking joint damage over time, showing joint-space narrowing and bone erosions. But they miss a lot of what is happening in the soft tissues. Ultrasound and MRI have become increasingly important for catching RA knee damage early.
A comparison study of ultrasound versus MRI in RA knees found that ultrasound had high sensitivity and specificity for detecting bone erosion, joint-space narrowing, and synovitis. Agreement between the two imaging methods was substantial for synovitis, joint effusion, and tendon-sheath inflammation, and nearly perfect for bone erosion. The practical upside is that ultrasound is cheaper, faster, and can be done in a clinic visit, making it a good option for monitoring how the knee is responding to treatment. MRI remains the gold standard for detailed evaluation of cartilage, menisci, and ligaments, particularly when surgery is being considered.
Beyond imaging, the fluid inside the joint itself carries useful information. Researchers have identified specific inflammatory molecules that are elevated in RA synovial fluid compared with osteoarthritis fluid. Among these, six biomarkers were significantly higher in active RA, including TNF-alpha, two interleukins, and three matrix-degrading enzymes called MMPs. These molecules are more than academic curiosities: they are the targets of many modern RA drugs, and their presence in joint fluid helps confirm that the knee inflammation is driven by RA rather than another process.
How RA Changes the Way You Walk
Knee involvement in RA doesn’t just cause pain when standing or climbing stairs. It reshapes the entire mechanics of walking. Biomechanical analyses show that people with RA knees develop what researchers describe as a “sparing” gait: the vertical push-off forces against the ground are lower than normal, the stride becomes more static and asymmetric, and the body recruits hip muscles more heavily to compensate for what the knee can no longer do comfortably. The gluteal muscles on the affected side work harder, and the forces through both hip joints increase across all planes of motion.
Kinematic studies break this down further. Patients with active knee inflammation show limited motion at the knee during the stance phase, when the foot is on the ground and the knee should be flexing and extending smoothly under load. In patients with established joint destruction, the swing phase (when the leg is moving forward in the air) becomes shortened and the knee moves through a smaller arc. These gait changes are not just inconveniences. They redistribute stress to the hips, ankles, and spine, which helps explain why RA patients with severe knee disease often develop pain in joints that may not be directly inflamed.
Drug Treatment and Slowing Knee Damage
The first-line systemic treatment for RA remains methotrexate, a conventional disease-modifying drug. For many patients, methotrexate alone or in combination with other conventional drugs controls inflammation well enough to prevent serious knee damage. But when the knee continues to deteriorate despite conventional therapy, biologic drugs become important.
A quantitative overview of 18 trials found that several biologic drugs, when added to methotrexate, were significantly better at slowing X-ray progression than methotrexate alone. Among biologic monotherapies (without methotrexate), tocilizumab, adalimumab, and etanercept outperformed methotrexate, with tocilizumab ranking first. In combination with methotrexate, etanercept, adalimumab, infliximab, certolizumab, tocilizumab, and rituximab all slowed radiographic damage effectively, with infliximab ranking first in both outcome measures used.
An important nuance is what happens once a patient reaches clinical remission, meaning their symptoms and lab markers suggest the disease is quiet. Even in remission, biologic drugs appear to offer a small additional edge over conventional drugs in preventing bone erosion. One observational study found that erosion progression over three years was 0.9% in patients on biologics versus 1.4% in those on conventional drugs. The difference was real but, as the authors noted, probably not meaningful from a clinical standpoint. Still, for the knee specifically, where even modest cartilage loss translates to pain and instability under load, any protection matters.
Looking specifically at large-joint damage, one study of patients on biologic therapy found progressive damage in about 21% of patients and 6% of individual joints. The strongest predictor of further damage was how much damage was already present. The practical message: early, aggressive treatment of knee inflammation offers the best chance of preserving the joint long term.
Injections for the RA Knee
When one knee is disproportionately inflamed despite systemic treatment, a corticosteroid injection directly into the joint can provide rapid relief. Evidence supports corticosteroid knee injections for RA at the highest level, with pain relief and functional improvement lasting months and, in some cases, up to a year.
A question that occasionally comes up is whether injecting a biologic drug directly into the knee might work better than a steroid. A randomized trial compared a single injection of etanercept (a TNF-blocker) with methylprednisolone (a corticosteroid) in RA knees. At four weeks, there was no significant difference in pain between the two groups, but the within-group improvements told a story: methylprednisolone produced a more marked reduction in both pain and swelling than etanercept. The corticosteroid group saw pain drop from a mean of about 47 to 25 on a 100-point scale, while the etanercept group went from about 41 to 33. For now, the standard intra-articular steroid injection remains the workhorse for local flares, while biologics do their best work when delivered systemically.
When Surgery Becomes Necessary
Surgery enters the picture when medications and injections can no longer control pain or preserve function. The two main surgical options for an RA knee are synovectomy and total knee replacement.
Synovectomy
Arthroscopic synovectomy removes the inflamed synovial lining through small incisions, aiming to reduce pain and slow damage without replacing the joint. Studies show that it decreases disease activity, improves function, and raises quality of life in patients with recurrent knee synovitis. However, the benefits do not last forever. A 14-year follow-up of patients who had combined arthroscopic and radiation synovectomy found that the joint survival rate, defined as not needing a total knee replacement, was about 88% at five years but dropped to roughly 54% at ten years and 40% at fourteen years. Synovectomy buys time, and for patients with active synovitis but relatively preserved cartilage, that time can be substantial. But most patients eventually progress to needing a knee replacement.
Total Knee Replacement
Total knee arthroplasty is the definitive surgical option when the joint is destroyed. RA patients tend to arrive at surgery in worse shape than osteoarthritis patients: preoperative pain and function scores are significantly worse. But the good news is that the gap largely closes after surgery. A large study found no independent association between having RA and worse pain or function outcomes at two years post-surgery, and satisfaction was high in both groups.
That said, RA patients face some additional surgical risks. A meta-analysis of over eight million knee replacements found that RA patients had roughly 60% higher odds of overall infection and about double the odds of deep infection compared with osteoarthritis patients. They also had a higher risk of periprosthetic fracture and slightly longer hospital stays. Reassuringly, there was no significant difference in revision rates, prosthetic loosening, or mortality between the two groups. A separate meta-analysis broadly agreed on the infection picture but also reported that post-operative knee function scores tend to be modestly lower in RA patients, though pain relief remains excellent.
Managing Medications Around Knee Surgery
One of the trickiest practical questions for RA patients facing knee surgery is what to do with their medications. The concern is that immunosuppressive drugs could increase infection risk or delay wound healing. Guidelines from the American College of Rheumatology and the American Association of Hip and Knee Surgeons recommend continuing conventional disease-modifying drugs like methotrexate through surgery but holding biologic drugs for one dosing interval beforehand. A separate recommendation suggests withholding biologics for at least twice their half-life before major procedures.
The reality, though, is that the evidence is not as clear-cut as those guidelines might suggest. An observational study of nearly 500 elective hip and knee replacements found that surgical site infections were not associated with ongoing use of disease-modifying drugs, including TNF-alpha inhibitors. The event rate was low, which limits how firmly conclusions can be drawn, but the investigators elected to keep their practice of continuing biologic treatment through surgery. The takeaway for patients is that this decision should be individualized: stopping biologics too far ahead of surgery risks a disease flare, while continuing them carries a theoretical infection risk. Your rheumatologist and surgeon need to coordinate on the timing.
Exercise and Rehabilitation
A persistent myth about RA knees is that exercise will make things worse. The opposite is closer to the truth. A systematic review of dynamic exercise therapy in RA found that it effectively increased aerobic fitness and muscle strength without worsening disease activity or pain. Radiographic progression was not clearly affected, meaning exercise did not appear to accelerate joint damage.
A study comparing strengthening exercises with aerobic exercises in patients with knee RA found that both reduced pain equally compared with a control group that did neither. But the two types of exercise had different secondary benefits: aerobic exercise produced greater improvements in walking ability and overall function, while strengthening exercises were better at increasing the knee’s range of motion. This suggests that a program combining both types gives the most complete benefit for an RA knee.
Practical points for exercising with an RA knee: low-impact activities like cycling, swimming, and water aerobics are generally easier on inflamed joints than running or jumping. During a flare, gentle range-of-motion exercises are usually better tolerated than resistance work. Strengthening the quadriceps is especially important because these muscles are the primary stabilizers of the knee, and RA-related weakness here accelerates the biomechanical problems described earlier.
When RA Leads to Osteoarthritis
An under-appreciated consequence of RA in the knee is the development of secondary osteoarthritis. People sometimes think of RA and osteoarthritis as entirely separate diseases, but chronic RA inflammation can actually set the stage for osteoarthritis to develop on top of it. The mechanism involves several pathways: persistent inflammation invades the joint capsule and bursa, destabilizing the joint. An unstable knee wears its remaining cartilage faster, and the ongoing inflammation impairs the cartilage’s ability to heal and remodel. A large population-based study in Taiwan confirmed that RA patients have an increased risk of developing osteoarthritis over time. This means that even when RA inflammation is brought under control, the structural damage it has already caused can continue to generate symptoms through a secondary osteoarthritic process.
Knee Problems in Juvenile Arthritis
When arthritis appears in children, the knee is one of the most commonly affected joints. Juvenile idiopathic arthritis encompasses several subtypes, and knee involvement can occur in nearly all of them. The concerns differ from adult RA in important ways. Beyond pain and swelling, persistent knee inflammation in a growing child can affect leg-length equality and overall growth. A prospective study following children with JIA found that height z-scores decreased significantly over three years, with about 39% of patients experiencing meaningful growth restriction. Growth impacts were largest in the systemic and psoriatic subtypes. For the knee specifically, chronic inflammation in one knee during a growth spurt can cause that leg to grow faster than the other, leading to a leg-length discrepancy that alters gait and posture.
Emerging Approaches to Cartilage Repair
Once cartilage is destroyed by RA, it does not grow back on its own. Current treatments manage inflammation and pain, but regenerating lost cartilage in an RA knee remains an unsolved problem. Mesenchymal stem cells are the most actively researched biological approach. These cells can differentiate into cartilage-forming cells and also have built-in immunosuppressive properties, which makes them theoretically attractive for RA, where both tissue repair and immune regulation are needed.
Recent work has expanded beyond simply injecting stem cells into a joint. Researchers are exploring exosomes, tiny vesicles shed by stem cells that carry anti-inflammatory signals, and bioengineered scaffolds made of natural or synthetic polymers that provide a physical framework for new cartilage to grow on. Lab studies have shown that stem cells harvested from the synovium of RA patients are no less capable of forming cartilage than cells from healthy donors, which is encouraging because it means a patient’s own tissue could theoretically serve as a source for repair. These approaches remain largely in the preclinical and early-trial stages, and no stem cell or scaffold therapy is yet standard-of-care for RA knees. But the field is moving quickly, and the combination of immune modulation and tissue engineering may eventually offer something that current drugs cannot: actual restoration of damaged joint surfaces.
How RA Knee Fluid Differs from Osteoarthritis Fluid
If you have ever had fluid drained from a swollen knee, you may have wondered what that fluid reveals about your disease. In RA, the synovial fluid is a window into the immune storm driving the damage. Compared with osteoarthritis fluid, RA synovial fluid contains significantly higher levels of TNF-alpha, interleukin-1 beta, and several matrix metalloproteinases, the enzymes that physically chew through cartilage. More recent proteomic work has identified dozens of autoantibodies in RA synovial fluid that are absent or much lower in osteoarthritis, including a newly identified cytokine, interferon alpha-2, whose role is still being worked out. These autoantibodies appear to be linked to pathways involved in neutrophil extracellular trap formation and activation of the NF-kB inflammatory cascade, both of which are central to RA’s destructive process.
What makes this clinically relevant, rather than just academic, is that these markers can help distinguish RA-driven knee inflammation from other causes when the diagnosis is uncertain. A swollen knee in someone without a clear RA history might be osteoarthritis, gout, infection, or early RA. The cytokine and autoantibody profile of the fluid can tilt the diagnosis and change the treatment plan entirely. Interestingly, the same research found that some osteoarthritis patients had synovial fluid profiles that looked surprisingly similar to RA, suggesting a subset of osteoarthritis may involve more immune-mediated damage than traditionally assumed.